2025-08-22 08:10Financial Performance - Revenue for Q2 2025 reached RMB 3,342 million, a 7.9% increase from Q1 2025 and a 13.9% increase year-over-year from Q2 2024 [14] - Net profit attributable to shareholders for Q2 2025 was RMB 396 million, a 29.5% increase from Q1 2025 but a 55.2% decrease year-over-year from Q2 2024 [14] - Non-IFRS adjusted net profit for Q2 2025 was RMB 406 million, reflecting a 16.3% increase from Q1 2025 and a 15.6% increase year-over-year [14] Revenue Breakdown - For 1H 2025, total revenue was RMB 6,441 million, a 14.9% increase compared to 1H 2024 [15] - New orders increased by over 10% year-over-year, with revenue from top 20 pharmaceutical companies growing by 48% [15] - Revenue composition: 88% from domestic delivery and 12% from overseas delivery [18] Client and Market Insights - Active clients exceeded 2,600, including over 480 new clients, with significant contributions from the top 20 pharmaceutical companies [16] - Revenue growth from North American clients was 11%, European clients 30.5%, and Chinese clients 15.5% [19] - The company maintains a target of 10-15% revenue growth for the full year 2025 [55] ESG and Sustainability Initiatives - The company achieved an AA rating in the latest MSCI ESG assessment [24] - It has joined the United Nations Global Compact and aims for the highest ESG ratings in the Asia-Pacific region by 2025 [28][29] - Efforts include achieving 100% renewable electricity usage in some facilities and expanding information security management systems [26] Operational Highlights - The company participated in 795 drug discovery projects and has a robust pipeline for long-term growth [16] - Clinical research services included 1,027 projects, with 89 in Phase III trials [36] - The company is enhancing its AI capabilities through partnerships and new technology integrations [16]